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Introduction
Pulmonary hypertension is a common complication of pul-
monary parenchymal diseases. Its presence is associated
with a poor prognosis in patients with severe chronic obstruc-
tive pulmonary disease (COPD) [1,2] and cystic fibrosis
[3,4]. Pulmonary hypertension is not uncommon among
patients awaiting lung transplantation, so this situation is fre-
quently dealt with during surgical or diagnostic procedures. In
these situations, vasodilator and inotropic drugs, mainly low-
dose dobutamine, are usually used in order to maintain hemo-
dynamic stability. However this approach may have a detri-
mental effect on gas exchange [5].
Recently, inhaled nitric oxide (INO) in combination with
oxygen has been used successfully to improve oxygenation
and pulmonary hemodynamics in patients with COPD and
acute respiratory distress syndrome [6]. However, the hemo-
dynamic effects of a combination therapy with nitric oxide
COPD = chronic obstructive pulmonary disease; CVP = central venous pressure; INO = inhaled nitric oxide; MAP = mean systemic arterial pres-
sure; MPAP = mean pulmonary arterial pressure; NO = nitric oxide; PAOP = pulmonary artery occluded pressure; PVRI = pulmonary vascular resis-
tance index; SVI = systemic vascular index; SVRI = systemic vascular resistance index; TPG = transpulmonary gradient.
Abstract
Introduction The use of low-dose dobutamine to maintain hemodynamic stability in pulmonary
hypertension may have a detrimental effect on gas exchange. The aim of this study was to investigate
whether inhaled nitric oxide (INO), dobutamine and a combination of the two have beneficial effects in
patients with end-stage airway lung disease and pulmonary hypertension.
Method Hemodynamic evaluation was assessed 10 min after the administration of each drug and of
their combination, in 28 candidates for lung transplantation.
Results Administration of INO caused a reduction in mean pulmonary arterial pressure (MPAP), an
increase in PaO2 with a significant reduction in venous admixture effect (Qs/Qt). Dobutamine
administration caused an increase in cardiac index and MPAP, with a decrease in PaO2 as a result of a
higher Qs/Qt. Administration of a combination of the two drugs caused an increase in the cardiac index
without MPAP modification and an increase in PaO2 and Qs/Qt.
Conclusion  Dobutamine and INO have complementary effects on pulmonary circulation. Their
association may be beneficial in the treatment of patients with mild to moderate pulmonary hypertension.
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(NO) and low-dose dobutamine in patients with severe
obstructive lung disease and pulmonary hypertension have
not yet been addressed.
In order to establish the preliminary bases for this therapeuti-
cal approach we investigated the acute hemodynamic effects
of INO, dobutamine, and the combination of the two in a
group of patients with mild to moderate pulmonary hyperten-
sion secondary to severe airway disease.
Materials and methods
Subjects
The study population was selected from among patients with
end-stage pulmonary disease secondary to airway disease
and pulmonary hypertension (with a mean pulmonary arterial
pressure >20 mmHg) who were evaluated for lung transplan-
tation at the University of Rome hospital ‘La Sapienza’. Eight
patients suffered from cystic fibrosis, nine from bronchiecta-
sis, and 11 from COPD. The demographic and clinical data
are summarized in Table 1. All patients required continuous
low-flow oxygen therapy and were being treated with inhaled
beta2-adrenergic drugs (albuterol 600–1200 µg/day), pred-
nisone (5–10 mg/day), and methylxanthines (theophylline
450–900 mg/day). Ten patients were treated with digoxin
(0.25 mg/day) and furosemide (20–40 mg/day).
Evaluation of the patients included taking a clinical history,
undertaking a physical examination, administering a chest
X-ray, and monitoring by echocardiography. None of the
patients had a history of systemic hypertension, valvular or
ischemic heart disease. Pulmonary function tests were under-
taken with a Med Graphics System 1085 (Medical Graphics
Corp., St Paul, MN, USA) according to American Thoracic
Society standards [7]. Functional residual capacity was mea-
sured by plethysmography; total lung capacity and residual
volume were calculated using standard formulae (Table 1). All
data are reported as a percentage of the predicted normal
value [8]. At echo-Doppler evaluation, all patients had normal
left ventricular function, but mild to moderate right ventricular
dilation was found in 10 patients. Tricuspid regurgitation was
present in 23 patients but only in three was it more than trivial.
All patients were in a stable hemodynamic condition and
were included in the study protocol after informed consent.
The protocol was approved by the institutional review board
for human studies.
Hemodynamic study
All patients underwent a complete hemodynamic evaluation
such as that required for routine screening prior to lung trans-
plantation at the University of Rome hospital. Under local
anesthesia a 7 F Swan-Ganz triple lumen thermodilution
catheter was inserted through the femoral vein and was posi-
tioned in the pulmonary artery. A polyethylene catheter was
introduced into the radial artery. Transducers were refer-
enced 5 cm below the sternal angle in the supine position.
Right atrial pressure (central venous pressure, CVP), mean
pulmonary arterial pressure (MPAP), mean pulmonary artery
occluded pressure (PAOP), and mean systemic arterial pres-
sure (MAP), were measured as the average of four respiratory
cycles. Transpulmonary gradient (TPG) was defined as
MAP–PAOP. Cardiac output was measured in triplicate by
thermodilution. Cardiac index, systemic vascular resistance
index (SVRI) and pulmonary vascular resistance index (PVRI)
were calculated using standard formulae.
Samples of arterial and mixed venous blood were analyzed for
oxygen pressure, carbon dioxide pressure, and pH using a
blood gas analyzer (Instrumentation Laboratory Model 1300;
Milan, Italy), which was calibrated with a proper gas mix with
oxygen concentration of 90%.
Anatomic shunt/venous admixture effect (Qs/Qt) was calcu-
lated according to Cotes [9], using the mass balance equation:
Qs/Qt(%) = CcO2–CaO2/CcO2–CvO2
where CcO2 is capillary content of O2, CaO2 is arterial
content of O2, and CvO2 is mixed venous content of O2. Arte-
rial, capillary, and mixed venous oxygen content were calcu-
lated as follows:
content = (Hb × 1.39 × % saturation) + (PO2 × 0.003).
Arterial and venous mixed PO2 and saturation were measured
on blood samples, capillary saturation was assumed to be
100%, while alveolar PO2 was calculated as (Pbar–47) ×
FiO2–PaCO2/R, where R = 0.8.
Study protocol
The protocol was single blinded: the patient breathed
through a face mask (oxygen or oxygen + INO) and received
an infusion (saline or dobutamine) throughout the study.
Table 1
Demographic and clinical characteristics of the study
population (28 patients)
Characteristic Mean (± SD)
Age (years) 38 ± 18
Sex (M/F) 10/11
Height (cm) 161 ± 12
Weight (kg) 56 ± 19
FVC (% predicted) 44 ± 12
FEV1 (% predicted) 28 ± 26
TLC (% predicted) 99 ± 26
RV (% predicted) 208 ± 67
FVC, forced vital capacity; FEV1, forced exhaled volume in 1 s; RV,
residual volume; TLC, total lung capacity.r
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Measurements were started after 20 min of quiet rest in order
to reach hemodynamic stability. A complete hemodynamic
profile was taken before each drug administration (baseline 1,
baseline 2, baseline 3), during inhalation of nitric oxide
(40 ppm for 10 min), dobutamine (10 µg/kg/min for 10 min),
and a combination of all the above. All tests were performed
while patients were breathing 100% O2 via a face mask, in
order to measure shunt.
Nitric oxide was obtained from a stock tank containing
500 ppm of nitric oxide in N2 and its administration was con-
trolled using two electrochemical cell monitors Politron NO
and NO2 (Drager; Lubeck, Germany) for INO and NO2 pro-
duced. Inspired O2 concentration was measured through a
connection to a gas-analyzer (Capnomac-Datex; Helsinki,
Finland). The sequence of drug challenge (INO, INO + dobut-
amine, dobutamine; or dobutamine, INO + dobutamine, INO)
was chosen randomly and each treatment started after hemo-
dynamic values returned to the baseline level (± 5%).
Statistical analysis
Data are reported as means ± standard deviation (SD). For
the sake of clarity the baseline column in the tables reflects
the mean of the three baselines prior to each drug challenge.
Comparison between each baseline and drug challenge was
made by a paired t-test. The effects of the various treatments
were compared by using one-way analysis of variance with
multiple dependent measures. If a significant difference was
found, a Duncan’s multiple range test was used to determine
the statistical significance among treatments. A level of
P < 0.05 was considered significant.
Results
Inhaled nitric oxide challenge
Taking the whole population into consideration, INO caused a
slight decrease in MPAP, PVRI, and TPG without significant
modifications in the other hemodynamic parameters
(Table 2). These modifications were accompanied by a strik-
ing increase in PaO2 and a significant reduction in venous
admixture effect.
The same trend was also observed when each disease group
was analyzed separately (Tables 3–5).
Dobutamine challenge
Dobutamine infusion caused an increase in cardiac index,
heart rate, systemic vascular index (SVI), and MPAP with no
change in CVP, PAOP, and MAP. PVRI and SVRI decreased
significantly (Table 2). There was also a decrease in PaO2
and a significant increase in Qs/Qt, with no change in PaCO2.
The same trend was also observed when each disease group
was analyzed separately (Tables 3–5).
Inhaled nitric oxide plus dobutamine challenge
The combination of INO and dobutamine caused a signifi-
cant increase in cardiac index, heart rate and SVI, without
modifying either MPAP or MAP, as a result of a significant
Available online http://ccforum.com/content/5/6/355
Table 2
Hemodynamic and gas exchange response to inhaled nitric oxide (INO), dobutamine, and to dobutamine plus INO in all patients.
The baseline values presented are the means of the three baseline studies assessed before each challenge
Baseline INO Dobutamine INO+Dobutamine
Cardiac index (l/min/m2) 3.2 ± 1.2 3.2 ± 1.2 4.7 ± 1.2** 4.4 ± 1.2**
Heart rate (beats/min) 87 ± 18 86 ± 17 113 ± 18** 109 ± 19**
SVI (ml/m2) 36 ± 10 37 ± 9 44 ± 16** 41 ± 11**
CVP (mmHg) 2.5 ± 2.8 3.1 ± 3.1 2.4 ± 2.5 2.7 ± 2.9
MPAP (mmHg) 26 ± 10 24 ± 9** 31 ± 15* 27 ± 12
PAOP (mmHg) 7 ± 3 7.4 ± 4 8 ± 4 7 ± 3
MPAP–PAOP (mmHg) 19 ± 10 17 ± 9** 23 ± 14 20 ± 11
PVRI (dyne/s/cm5/m2) 535 ± 285 477 ± 293* 441 ± 331 416 ± 265**
MAP (mmHg) 86 ± 11 87 ± 10 86 ± 10 85 ± 10
SVRI (dyne/s/cm5/m2) 2363 ± 764 2348 ± 786 1346 ± 243** 1614 ± 439**
Qs/Qt (%) 23 ± 5 20 ± 5* 26 ± 5** 25 ± 7
PaO2/FiO2 (mmHg) 327 ± 90 418 ± 104** 296 ± 90* 390 ± 111**
PaCO2 (mmHg) 51 ± 12 52 ± 12 51 ± 13 50 ± 13
*P < 0.05; **P < 0.01. CVP, cardiovenous pressure; INO, inhaled nitric oxide; MAP, mean systemic arterial pressure; MPAP, mean pulmonary
arterial pressure; PAOP, pulmonary artery occluded pressure; PVRI, pulmonary vascular resistance index; SVI, systemic vascular index; SVRI,
systemic vascular resistance index.fall in pulmonary and systemic vascular resistance. CVP and
PAOP had no significant change. There was a significant
increase in PaO2 and slight but not significant increase in
Qs/Qt with no change in PaCO2. The same trend was also
observed when each disease group was analyzed separately
(Tables 3–5).
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Table 3
Hemodynamic and gas exchange response to inhaled nitric oxide (INO), dobutamine, and INO plus dobutamine in bronchiectasis
(9 patients)
Baseline 1 INO Dobutamine INO+Dobutamine
Cardiac index (l/min/m2) 3.9 ± 1.9 3.8 ± 1.5 5.6 ± 1.4 4.5 ± 0.3
Heart rate (beats/min) 87 ± 17 85 ± 12 115 ± 25 114 ± 23*
SVI (ml/m2) 43 ± 15 43 ± 13 53 ± 27 42 ± 12
CVP (mmHg) 3.2 ± 2.8 4 ± 3 3.2 ± 2.7 3.2 ± 3.9
MPAP (mmHg) 33 ± 16 28 ± 14 37 ± 17 36 ± 17
PAOP (mmHg) 9.4 ± 2 7.8 ± 1 12.5 ± 5 9.2 ± 3.3
MPAP–PAOP (mmHg) 24 ± 15 20 ± 14 24 ± 17 27 ± 18
PVRI (dyne/s/cm5/m2) 781 ± 424 662 ± 355 569 ± 321 641 ± 335*
MAP (mmHg) 86 ± 10 88 ± 9 90 ± 14 79 ± 11
SVRI (dyne/s/cm5/m2) 1919 ± 684 1974 ± 712 1272 ± 256 1391 ± 237*
Qs/Qt (%) 19 ± 5 11 ± 4* 24 ± 7 15 ± 12
PaO2/FiO2 (mmHg) 366 ± 113 448 ± 92 344 ± 95 435 ± 115
PaCO2 (mmHg) 51 ± 20 52 ± 23 53 ± 24 56 ± 23
*P < 0.05; **P < 0.01. CVP, cardiovenous pressure; INO, inhaled nitric oxide; MAP, mean systemic arterial pressure; MPAP, mean pulmonary
arterial pressure; PAOP, pulmonary artery occluded pressure; PVRI, pulmonary vascular resistance index; SVI, systemic vascular index; SVRI,
systemic vascular resistance index.
Table 4
Hemodynamic and gas exchange response to inhaled nitric oxide (INO), dobutamine, and INO plus dobutamine in cystic fibrosis
(8 patients)
Baseline INO Dobutamine INO+Dobutamine
Cardiac index (l/min/m2) 3.6 ± 0.6 3.6 ± 0.5 5.1±0.6 4.7±0.5**
Heart rate (beats/min) 90 ± 26 90 ± 25 102 ± 22 104 ± 18
SVI (ml/m2) 43 ± 12 43 ± 10 52 ± 10 47 ± 7
CVP (mmHg) 1.4 ± 1.9 1.6 ± 2.1 1.9 ± 2.4 1.4 ± 2
MPAP (mmHg) 24 ± 4 22 ± 3 26 ± 5 24 ± 3
PAOP (mmHg) 5.7 ± 2.7 6.5 ± 3.5 6.2 ± 3.3 5.6 ± 2.6
MPAP–PAOP (mmHg) 18 ± 2 16 ± 2* 20 ± 2 18 ± 3
PVRI (dyne/s/cm5/m2) 591 ± 148 548 ± 140 448 ± 96* 460 ± 98*
MAP (mmHg)  83 ± 15 83 ± 11 87 ± 13 89 ± 13
SVRI (dyne/s/cm5/m2) 1826 ± 261 1825 ± 230 1371 ± 193 1495 ± 197**
Qs/Qt (%) 20 ± 7 17 ± 4 30 ± 6* 22 ± 5
PaO2/FiO2 (mmHg) 276 ± 56 350 ± 48* 260 ± 56 319 ± 65
PaCO2 (mmHg) 54 ± 11 55 ± 11 54 ± 12 53 ± 12
*P < 0.05; **P < 0.01. CVP, cardiovenous pressure; INO, inhaled nitric oxide; MAP, mean systemic arterial pressure; MPAP, mean pulmonary
arterial pressure; PAOP, pulmonary artery occluded pressure; PVRI, pulmonary vascular resistance index; SVI, systemic vascular index; SVRI,
systemic vascular resistance index.Comparison of treatments
Only INO caused a light but statistically significant reduction
of MPAP and TPG without changes in cardiac index or SVRI.
On the other hand, only dobutamine and the combination of
the two drugs elicited an increase in cardiac index with a
reduction in SVRI.
In order to analyze pulmonary hemodynamic response, we
plotted the modification of TPG in function of pulmonary flow
on a pressure-flow chart with isoresistance lines passing
through the origin of the axis. Three different patterns were
observed: INO caused a downward shift through lower isore-
sistance lines; dobutamine caused a shift right and upwards,
almost parallel to the isoresistance line representing the
flow–pressure relationship for a vascular resistance equal to
300 dynes/s/cm5; and the combined treatment showed an
intermediate reaction with a rightward shift (Figure 1).
Arterial blood gases analysis showed no change in arterial
CO2 tension during the administration of the three regimens.
On the other hand, PaO2 increased with INO therapy and the
combined therapy with dobutamine and INO, while it
decreased when dobutamine was used by itself.
This behavior was congruent with the reduction in Qs/Qt
during treatment with INO and the increase in Qs/Qt during
treatment with dobutamine alone. During therapy with the
combination of the two drugs (INO + dobutamine) Qs/Qt
increased slightly, thus the increase in PaO2 is mainly a result
of an increase in mixed venous oxygen saturation.
Discussion
Inhaled nitric oxide challenge
As was expected, our study confirms that INO has a selective
vasodilator effect on pulmonary circulation in patients with
severe airway disease. Treatment with INO slightly reduced
MPAP, PVRI, and TPG, with no changes in cardiac index,
MAP and SVRI. Its actual vasodilator effect is documented by
Available online http://ccforum.com/content/5/6/355
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Figure 1
Flow–pressure diagram showing the difference of MPAP and PAOP
(MPAP–PAOP) and cardiac index. The dashed lines indicate the
isoresistance lines from 600 to 300 dyne/s/cm5. INO, inhaled nitric
oxide; MPAP, mean pulmonary arterial pressure; PAOP, pulmonary
artery occluded pressure.
Table 5
Hemodynamic and gas exchange response to inhaled nitric oxide (INO), dobutamine, and INO plus dobutamine in severe chronic
obstructive pulmonary disease (COPD) (11 patients)
Baseline INO Dobutamine INO+Dobutamine
Cardiac index (l/min/m2) 3.2 ± 1.9 3.2 ± 2.3 5.0 ± 2.7 4.7 ± 2.4**
Heart rate (beats/min) 83 ± 28 83 ± 30 104 ± 28 101 ± 29*
SVI (ml/m2) 38 ± 11 39 ± 13 49 ± 18 47 ± 19
CVP (mmHg) 2.5 ± 3 2.5 ± 3.1 2.0 ± 1.8 2.0 ± 2.0
MPAP (mmHg) 23 ± 7 21 ± 7 25 ± 8 24 ± 9
PAOP (mmHg) 6.6 ± 4.5 6.0 ± 4.9 5.3 ± 4.7 5.0 ± 4.0
MPAP–PAOP (mmHg) 16 ± 8 15 ± 6 19 ± 7* 19 ± 9
PVRI (dyne/s/cm5/m2) 671 ± 277 601 ± 247 471 ± 262* 492 ± 300*
MAP (mmHg) 87 ± 12 89 ± 11 91 ± 9 93 ± 12
SVRI (dyne/s/cm5/m2) 2524 ± 873 2625 ± 1012 1654 ± 541 1824 ± 683**
Qs/Qt (%) 23 ± 11 15 ± 6 28 ± 10* 17 ± 5
PaO2/FiO2 (mmHg) 322 ± 115 442 ± 103* 310 ± 93 419 ± 90*
PaCO2 (mmHg) 45 ± 11 44 ± 11 43 ± 11 45 ± 13
*P < 0.05; **P < 0.01. CVP, cardiovenous pressure; INO, inhaled nitric oxide; MAP, mean systemic arterial pressure; MPAP, mean pulmonary
arterial pressure; PAOP, pulmonary artery occluded pressure; PVRI, pulmonary vascular resistance index; SVI, systemic vascular index; SVRI,
systemic vascular resistance index.the reduction in TPG, and a downward shift of pulmonary
pressure–flow relationship. The magnitude of MPAP reduc-
tion in our study population was smaller than that reported in
other studies [10,11]. These differences can be reconciled
considering that in our study patients were on 100% oxygen
and, possibly, with a complete abolition of hypoxic vasocon-
striction. Moreover, the severity of lung disease and the vari-
ability in vascular responsiveness can explain this difference.
The relevant finding was that the vasodilator effect of INO was
accompanied by an improvement in arterial oxygenation. Previ-
ous studies demonstrated that INO may improve or worsen
arterial oxygenation in patients with COPD. In severe COPD,
Barbera et al. [11] demonstrated that INO, when administered
in room air, impairs pulmonary alveolar ventilation/capillary flow
ratio (VA/QC) and slightly reduces arterial oxygenation, while
Moinard et al. [12] observed no change in PaO2.
On the other hand, Yoshida et al. [13] and Germann et al.
[14] observed an increase in PaO2 and a reduction of pul-
monary venous admixture using low-dose nitric oxide
(5–20 ppm) in combination with oxygen.
Our data are in agreement with those two studies. By com-
bining INO with oxygen, it is conceivable that, in alveolar units
with low VA/Qc, the increase in alveolar PO2, resulting from
the high FiO2, matched the improved alveolar perfusion, mini-
mizing the worsening of pulmonary VA/Qc seen during the
administration of INO alone [13].
Dobutamine challenge
The effect of dobutamine on pulmonary circulation has not
been extensively assessed in patients with mild to moderate
pulmonary hypertension. In two small studies, dobutamine
increased cardiac output and improved oxygen transport and
oxygenation in patients with massive pulmonary embolism
[15,16]. Experimental studies in dogs with pulmonary hyper-
tension secondary to embolization of the pulmonary vascular
bed demonstrated that dobutamine increases the cardiac
index and decreases calculated PVRI. However, pulmonary
pressure–flow plots suggest that these findings are not a
result of vasodilation [17].
In the study reported here, dobutamine infusion showed
similar hemodynamic effects. Dobutamine caused a significant
increase in the cardiac index, with a concomitant reduction in
SVRI and PVRI. The reduction in PVRI was not proportional to
the increase in the cardiac index, leading to an increase in
MPAP. This behavior could be explained mainly as a recruit-
ment of vessels rather than as a real vasodilator effect. It is
noteworthy that the pressure–flow plot showed a slope very
close to that of the isoresistance line equal to
300 dynes/s/cm5. If we accept the viscoelastic model of the
pulmonary circulation, this is the case in which the vascular
closing pressure is higher than PAOP and should be consid-
ered as the effective outflow pressure for the pulmonary vas-
cular bed. Considering PAOP as outflow pressure, the
transpulmonary gradient is overestimated by the calculation of
pulmonary vascular resistance, and it becomes flow-depen-
dent even if no vasodilation has occurred [18]. The prevalent
role of vascular recruitment as a mechanism in pulmonary vas-
cular resistance reduction during dobutamine therapy is sup-
ported by the concomitant reduction in arterial oxygenation
and the increase in pulmonary Qs/Qt. This strongly suggests a
worsening of regional VA/QC as a result of an increased perfu-
sion of poorly or unventilated areas of the lung.
Inhaled nitric oxide plus dobutamine challenge
To our knowledge, the interaction of INO and dobutamine on
the pulmonary circulation has not been previously reported.
Our results indicate that the combined use of both drugs pro-
duces a complementary effect which improves circulation
and gas exchange. The combination of both drugs causes an
increase in cardiac index but no change in MPAP. This sug-
gests that the increase in the cardiac index induced by dobut-
amine is counterbalanced by the concomitant actual
pulmonary vasodilation induced by NO. This interpretation is
supported further by analysis of the pulmonary pressure–flow
relationship: during administration of the combination of the
two drugs the line has a slope intermediate between that of
dobutamine and INO when each is given alone.
The other relevant finding is that the favorable hemodynamic
effects are not associated with a deterioration in gas
exchange, probably because of the vasodilatory effect of INO,
which is evident in well-ventilated areas of the lung.
In accordance with the results of the present study, the algo-
rithm reported in Figure 2 may be suggested as a guide in the
management of patients with mild to moderate secondary
pulmonary hypertension in cases of acute cardiorespiratory
decompensation.
Inhaled nitric oxide and dobutamine have significant hemody-
namic effects in mild to moderate pulmonary hypertension.
Nitric oxide has a real, selective pulmonary vasodilating effect
accompanied by an improvement in arterial oxygenation, but
no change in cardiac output. Dobutamine, on the other hand,
increases pulmonary blood flow in the face of increasing
mean pulmonary pressure and a decrease in PaO2. The com-
bination of the two drugs shows more favorable effects. In
fact, the increase in cardiac index is associated with no modi-
fication in MPAP, and an increase in PaO2. These data show
that INO and dobutamine have a complementary beneficial
action, further studies are warranted to examine their use as a
therapeutic option in right ventricular failure during exacerba-
tions of chronic pulmonary disease.
Study limitation
Patients with different diseases but who shared a common
physiopathology (severe airways disease) were included in
this study. Although the small number of patients in each
Critical Care    December 2001 Vol 5 No 6 Vizza et al.group did not allow a direct statistical comparison to be
drawn between them, the results are consistent.
All patients were studied while breathing 100% O2 in an
attempt to measure the true shunt. Considering the high value
of shunt in our population (23%) compared to that reported in
the literature [19], it is possible that the severity of airways
impairment prevented a complete alveolar denitrogenification
leading to the measurement of a venous mixture effect.
The use of low-dose dobutamine as inotropic support in right
ventricular failure is a regular practice in an intensive care
setting or in the operating room. It could be argued that its
use in patients with cor pulmonale could have detrimental
effects, but in the short term the beneficial hemodynamic
effects (increased cardiac output and systemic oxygen deliv-
ery) usually outweigh the negative effects (increased right
ventricular work and oxygen demand).
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Figure 2
Decisional algorithm according to the different values of cardic index
and the different values of MPAP and PAOP (MPAP–PAOP) in cases
of acute cardiac decompensation. =, low TPG; ↑, moderate TPG; ↑↑,
high TPG. INO, inhaled nitric oxide; MPAP, mean pulmonary arterial
pressure; PAOP, pulmonary artery occluded pressure; TPG,
transpulmonary gradient.